External ValidatIon Trial of ASTER Trial (EVITA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01332240|
Recruitment Status : Unknown
Verified April 2011 by Universitaire Ziekenhuizen Leuven.
Recruitment status was: Recruiting
First Posted : April 11, 2011
Last Update Posted : October 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Stage III Lung Cancer||Procedure: Endoscopic ultrasonography||Not Applicable|
Background : The observation made by the ASTER investigators might be criticized as all procedures were performed in highly experienced centers. To date, the number of mediastinoscopies needed to detect one additional N2/3 disease in the routine clinical practice of chest physician performing endosonography for mediastinal staging is unknown. The investigators therefore seek to answer whether a negative endosonography should routinely be followed by mediastinoscopy in day to day clinical practice.
Aim : As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is widely spread in Belgium, the investigators aimed to determine the number of mediastinoscopies needed to detect one additional mediastinal lymph node invasion during routine clinical practice.
Setting : centers in Belgium with EBUS-TBNA and/or EUS-FNA experience in at least 20 patients agreed to participate and will include their patients.
Design : Prospective national observational multicenter study. All patients with clinical N2/3 disease based on CT and/or PET requiring invasive mediastinal staging will primarily undergo invasive mediastinal staging with endosonography (EBUS +/- EUS). A subsequent cervical mediastinoscopy will be performed in case no mediastinal lymph node involvement was found with endosonography. Local surgeons perform these procedures according to their institutional practice. Thoracotomy with mediastinal lymph node dissection will be the gold standard for invasive mediastinal staging, in case no mediastinal lymph node metastases were found during clinical staging including endosonography and mediastinoscopy.
Patients : The study will include 255 patients, based on the calculation of 15 consecutive patients in each participating center, in order to validate the ASTER data.
Primary endpoint : The number of mediastinoscopies needed to detect one additional N2/3.
Secondary endpoints : The number of mediastinal lymph nodes stations sampled with endosonography ; the median size of largest mediastinal lymph node sampled; characteristics of mediastinal nodal disease missed by endosonography.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||255 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||External ValidatIon Trial of Aster: the Need for Surgical Staging After Echo-endoscopic Mediastinal Staging in Clinical N2/3 Lung Cancer|
|Study Start Date :||April 2011|
|Estimated Primary Completion Date :||April 2013|
|Estimated Study Completion Date :||July 2013|
Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
Procedure: Endoscopic ultrasonography
in order to stage the mediastinum
- The number of mediastinoscopies needed to detect one additional N2/3 [ Time Frame: 1 month ]Efficacy
- The number of mediastinal lymph nodes stations sampled with endosonography [ Time Frame: 1 month ]Characteristics of nodal staging; the median size of largest mediastinal lymph node sampled; characteristics of mediastinal nodal disease missed by endosonography.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01332240
|Contact: Christophe Dooms, MD, PhD||0032 16 firstname.lastname@example.org|
|Contact: Kurt Tournoy, MD, PhDemail@example.com|
|Onze Lieve Vrouw Ziekenhuis||Withdrawn|
|Contact: Danny Galdermans|
|Sub-Investigator: Danny Galdermans|
|Contact: Andre Heremans|
|Sub-Investigator: Andre Heremans|
|Sint-Jan Ziekenhuis Brugge||Recruiting|
|Contact: Rebecca De pauw|
|Sub-Investigator: Rebecca De Pauw|
|Hopital Erasme Brussels||Recruiting|
|Contact: Dimitri Leduc|
|Sub-Investigator: Dimitri Leduc|
|Centre Hospitalier Universitaire de Charleroi||Recruiting|
|Contact: Philippe Pierard|
|Sub-Investigator: Philippe Pierard|
|Contact: Elke Vandenbroucke|
|Sub-Investigator: Elke Vandenbroucke|
|Universitair Ziekenhuis Antwerpen||Recruiting|
|Contact: Paul Germonprez|
|Sub-Investigator: Paul Germonprez|
|Contact: Karin Pat|
|Sub-Investigator: Karin Pat|
|Univeristair Ziekenhuis Brussel||Recruiting|
|Contact: Tom De Keukeleire|
|Sub-Investigator: Tom De Keukeleire|
|Center Hospitalier Jolimont||Recruiting|
|La Louvière, Belgium|
|Contact: Frederic Clinckart|
|Sub-Investigator: Fréderic Clinckart|
|Contact: Antoine Bolly|
|Sub-Investigator: Antoine Bolly|
|Contact: Christophe Pollefliet|
|Sub-Investigator: Christophe Pollefliet|
|Heilig Hart Ziekenhuis||Recruiting|
|Contact: Ingel Demedts|
|Sub-Investigator: Ingel Demedts|
|Sint-Elisabeth en Sint-Jozef ziekenhuis||Recruiting|
|Contact: Peter Driesen|
|Sub-Investigator: Peter Driesen|
|Contact: Sofie Van Grieken|
|Sub-Investigator: Sofie Van grieken|
|Contact: Thiery Pieters|
|Sub-Investigator: Thiery Pieters|
|Principal Investigator:||Christophe Dooms||Universitaire Ziekenhuizen Leuven|
|Principal Investigator:||Kurt Tournoy||University Hospital Ghent Belgium|